Influencing factors of pneumonitis in the period of thoracic radiotherapy combined with immunotherapy

Abstract

Abstract:

The combination of thoracic radiotherapy and immunotherapy is increasingly widely used in clinical practice，which not only brings survival benefits but also increases the incidence of pneumonitis. The occurrence of pneumonitis affects the subsequent immunotherapy and can be life-threatening in severe cases. The occurrence and severity of pneumonitis after combination therapy depends on a variety of factors，including patient's age，physical strength，pulmonary function，race，combination therapy mode，radiotherapy dose parameters，type of immune checkpoint inhibitor，history of checkpoint inhibitor-related pneumonitis or radiation pneumonitis，serum indexes and so on. At present，further research is needed to find out the influencing factors of the occurrence and severity of pneumonitis attributed to combined therapy，so as to better avoid，predict，identify and treat related pneumonitis in clinical practice.

Key words:Thoracic radiotherapy,Immunotherapy,Pneumonitis

Huang Huayu, Gong Hongyun, Song Qibin. Influencing factors of pneumonitis in the period of thoracic radiotherapy combined with immunotherapy[J]. Journal of International Oncology, 2023, 50(2): 102-106.

References39

[1]	Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest, 2014, 124(2): 687-695. DOI: 10.1172/JCI67313. doi:10.1172/JCI67313pmid:24382348
[2]	Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen[J]. Cancer Immunol Res, 2015, 3(4): 345-355. DOI: 10.1158/2326-6066.CIR-14-0196. doi:10.1158/2326-6066.CIR-14-0196pmid:25527358
[3]	Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiothe-rapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial[J]. Lancet Oncol, 2017, 18(7): 895-903. DOI: 10.1016/S1470-2045(17)30380-7. doi:S1470-2045(17)30380-7pmid:28551359
[4]	Faivre-Finn C, Vicente D, Kurata T, et al. Four-year survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC-an update from the PACIFIC trial[J]. J Thorac Oncol, 2021, 16(5): 860-867. DOI: 10.1016/j.jtho.2020.12.015. doi:10.1016/j.jtho.2020.12.015pmid:33476803
[5]	Yamaguchi O, Kaira K, Hashimoto K, et al. Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab[J]. Thorac Cancer, 2019, 10(4): 992-1000. DOI: 10.1111/1759-7714.13044. doi:10.1111/1759-7714.13044pmid:30888716
[6]	Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review[J]. JAMA Oncol, 2016, 2(10): 1346-1353. DOI: 10.1001/jamaoncol.2016.1051. doi:10.1001/jamaoncol.2016.1051pmid:27367787
[7]	Sheng Y, Chen K, Jiang W, et al. PD-1 restrains IL-17A production from γδ T cells to modulate acute radiation-induced lung injury[J]. Transl Lung Cancer Res, 2021, 10(2): 685-698. DOI: 10.21037/tlcr-20-838. doi:10.21037/tlcr-20-838
[8]	Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemora-diotherapy in stage Ⅲ non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(20): 1919-1929. DOI: 10.1056/NEJMoa1709937. doi:10.1056/NEJMoa1709937
[9]	Durm GA, Jabbour SK, Althouse SK, et al. A phase 2 trial of conso-lidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage Ⅲ non-small cell lung cancer: Hoosier cancer research network LUN 14-179[J]. Cancer, 2020, 126(19): 4353-4361. DOI: 10.1002/cncr.33083. doi:10.1002/cncr.33083
[10]	Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembro-lizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial[J]. JAMA Oncol, 2019, 5(9): 1276-1282. DOI: 10.1001/jamaoncol.2019.1478. doi:10.1001/jamaoncol.2019.1478
[11]	Wang Y, Zhang T, Huang Y, et al. Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage Ⅲ non-small cell lung cancer: a systematic review and meta-analysis[J]. Int J Radiat Oncol Biol Phys, 2022, 112(5): 1154-1164. DOI: 10.1016/j.ijrobp.2021.12.150. doi:10.1016/j.ijrobp.2021.12.150
[12]	Glick D, Lyen S, Kandel S, et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival in patients treated with lung stereotactic body radiation therapy (SBRT)[J]. Clin Lung Cancer, 2018, 19(2): e219-e226. DOI: 10.1016/j.cllc.2017.06.021. doi:10.1016/j.cllc.2017.06.021
[13]	Shibaki R, Murakami S, Matsumoto Y, et al. Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody[J]. Cancer Immunol Immuno-ther, 2020, 69(1): 15-22. DOI: 10.1007/s00262-019-02431-8. doi:10.1007/s00262-019-02431-8
[14]	Mayahara H, Uehara K, Harada A, et al. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer[J]. Radiat Oncol, 2022, 17(1): 7. DOI: 10.1186/s13014-021-01979-z. doi:10.1186/s13014-021-01979-zpmid:35033139
[15]	Faehling M, Schulz C, Laack H, et al. PACIFIC subgroup analysis: pneumonitis in stage Ⅲ, unresectable NSCLC patients treated with durvalumab vs. placebo after CRT[J]. Pneumologie, 2019, 73(S1): P272. DOI: 10.1055/s-0039-1678247. doi:10.1055/s-0039-1678247
[16]	Zhang T, Xu K, Bi N, et al. Efficacy and safety of immune check-point inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage Ⅲ non-small cell lung cancer: Chinese multicenter report and literature review[J]. Thorac Cancer, 2020, 11(10): 2916-2923. DOI: 10.1111/1759-7714.13631. doi:10.1111/1759-7714.13631pmid:32833338
[17]	Fukui T, Hosotani S, Soda I, et al. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab[J]. Thorac Cancer, 2020, 11(4): 1005-1014. DOI: 10.1111/1759-7714.13357. doi:10.1111/1759-7714.13357pmid:32057187
[18]	Wang L, Bi N. TGF-beta1 gene polymorphisms for anticipating radiation-induced pneumonitis in non-small-cell lung cancer: different ethnic association[J]. J Clin Oncol, 2010, 28(30): e621-e622. DOI: 10.1200/JCO.2010.31.0458. doi:10.1200/JCO.2010.31.0458
[19]	Inoue H, Okamoto I. Immune checkpoint inhibitors for the treatment of unresectable stage Ⅲ non-small cell lung cancer: emerging mechanisms and perspectives[J]. Lung Cancer (Auckl), 2019, 10: 161-170. DOI: 10.2147/LCTT.S184380. doi:10.2147/LCTT.S184380
[20]	Peters S, Felip E, Dafni U, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage Ⅲ non-small cell lung cancer-the ETOP NICOLAS trial[J]. Lung Cancer, 2019, 133: 83-87. DOI: 10.1016/j.lungcan.2019.05.001. doi:S0169-5002(19)30441-6pmid:31200833
[21]	Jabbour SK, Lee KH, Frost N, et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage Ⅲ non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial[J]. JAMA Oncol, 2021, 7(9): 1-9. DOI: 10.1001/jamaoncol.2021.2301. doi:10.1001/jamaoncol.2021.2301
[22]	Jabbour SK, Berman AT, Decker RH, et al. Phase 1 trial of pem-brolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: a nonrandomized controlled trial[J]. JAMA Oncol, 2020, 6(6): 848-855. DOI: 10.1001/jamaoncol.2019.6731. doi:10.1001/jamaoncol.2019.6731pmid:32077891
[23]	Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects[J]. Nat Rev Clin Oncol, 2019, 16(2): 123-135. DOI: 10.1038/s41571-018-0119-7. doi:10.1038/s41571-018-0119-7pmid:30401936
[24]	Voong KR, Hazell SZ, Fu W, et al. Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer[J]. Clin Lung Cancer, 2019, 20(4): e470-e479. DOI: 10.1016/j.cllc.2019.02.018. doi:10.1016/j.cllc.2019.02.018
[25]	Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneu-monitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis[J]. Int J Radiat Oncol Biol Phys, 2013, 85(2): 444-450. DOI: 10.1016/j.ijrobp.2012.04.043. doi:10.1016/j.ijrobp.2012.04.043
[26]	Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial[J]. J Clin Oncol, 2017, 35(1): 56-62. DOI: 10.1200/JCO.2016.69.1378. doi:10.1200/JCO.2016.69.1378pmid:28034064
[27]	Saito G, Oya Y, Taniguchi Y, et al. Real-world survey of pneumo-nitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)[J]. Lung Cancer, 2021, 161: 86-93. DOI: 10.1016/j.lungcan.2021.08.019. doi:10.1016/j.lungcan.2021.08.019pmid:34543942
[28]	Jung HA, Noh JM, Sun JM, et al. Real world data of durvalumab consolidation after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. Lung Cancer, 2020, 146: 23-29. DOI: 10.1016/j.lungcan.2020.05.035. doi:10.1016/j.lungcan.2020.05.035
[29]	Chen D, Menon H, Verma V, et al. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials[J]. J Immunother Cancer, 2020, 8(1): e000492. DOI: 10.1136/jitc-2019-000492. doi:10.1136/jitc-2019-000492
[30]	Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity[J]. CA Cancer J Clin, 2020, 70(2): 86-104. DOI: 10.3322/caac.21596. doi:10.3322/caac.21596
[31]	Lin SH, Lin Y, Yao L, et al. Phase Ⅱ trial of concurrent atezo-lizumab with chemoradiation for unresectable NSCLC[J]. J Thorac Oncol, 2020, 15(2): 248-257. DOI: 10.1016/j.jtho.2019.10.024. doi:10.1016/j.jtho.2019.10.024
[32]	Xiao Y, Yu S, Zhu B, et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance[J]. J Exp Med, 2014, 211(5): 943-959. DOI: 10.1084/jem.20130790. doi:10.1084/jem.20130790
[33]	Tian S, Switchenko JM, Buchwald ZS, et al. Lung stereotactic body radiation therapy and concurrent immunotherapy: a multicenter safety and toxicity analysis[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1): 304-313. DOI: 10.1016/j.ijrobp.2019.12.030. doi:10.1016/j.ijrobp.2019.12.030
[34]	Shaverdian N, Beattie J, Thor M, et al. Safety of thoracic radio-therapy in patients with prior immune-related adverse events from immune checkpoint inhibitors[J]. Ann Oncol, 2020, 31(12): 1719-1724. DOI: 10.1016/j.annonc.2020.09.016. doi:10.1016/j.annonc.2020.09.016pmid:33010460
[35]	Tamiya A, Tamiya M, Nakahama K, et al. Correlation of radiation pneumonitis history before nivolumab with onset of interstitial lung disease and progression-free survival of patients with pre-treated advanced non-small cell lung cancer[J]. Anticancer Res, 2017, 37(9): 5199-5205. DOI: 10.21873/anticanres.11943. doi:10.21873/anticanres.11943pmid:28870955
[36]	Wang F, Luo Y, Tian X, et al. Impact of radiotherapy concurrent with anti-PD-1 therapy on the lung tissue of tumor-bearing mice[J]. Radiat Res, 2019, 191(3): 271-277. DOI: 10.1667/RR15182.1. doi:10.1667/RR15182.1pmid:30694722
[37]	Geng Y, Su S, Cao L, et al. Effect of PD-1 inhibitor combined with X-ray irradiation on the inflammatory microenvironment and lung tissue injury in mice[J]. J Inflamm Res, 2022, 15: 545-556. DOI: 10.2147/JIR.S350112. doi:10.2147/JIR.S350112pmid:35115804
[38]	Schoenfeld JD, Nishino M, Severgnini M, et al. Pneumonitis re-sulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features[J]. J Immunother Cancer, 2019, 7(1): 112. DOI: 10.1186/s40425-019-0583-3. doi:10.1186/s40425-019-0583-3pmid:31014385
[39]	Zeng J, Rengan R, Santana-Davila R, et al. Abstract 6497: early assessment of liquid biomarkers to predict pneumonitis after chemoradiation in patients with locally advanced non-small cell lung cancer (LA-NSCLC)[J]. Cancer Res, 2020, 80(16_Supplement): 6497. DOI: 10.1158/1538-7445.AM2020-6497. doi:10.1158/1538-7445.AM2020-6497